AIM2 and neoplasm: This subsequently triggers absent in melanoma 2 (AIM2)/caspase‐1/gasdermin D (GSDMD)‐mediated pyroptosis, thereby enhancing tumor immunity and the efficacy of anti‐PD‐L1 immunotherapy in both microsatellite instable (MSI) and microsatellite stable (MSS) tumor cells.